| Dermatitis |
1 |
1 |
| Conjunctivitis |
0 |
0.57 |
| Atopic Dermatitis |
0 |
0.99 |
| Orbit |
0 |
0.46 |
| Biologic Therapy |
0 |
0.45 |
| Cornea and External Disease |
0 |
0.36 |
| Clinical Research |
0 |
0.27 |
| Corticosteroids |
0 |
0.27 |
| Face |
0 |
0.27 |
| Healthcare and Medical Technology |
0 |
0.27 |
| Pruritus |
0 |
0.27 |
| Staphylococcal Infection |
0 |
0.27 |
| Staphylococcus Aureus Infection |
0 |
0.27 |
| Topical Corticosteroid |
0 |
0.26 |
| Ocular Allergy |
0 |
0.25 |
| Allergic Conjunctivitis |
0 |
0.19 |
| Adverse Effects |
0 |
0.18 |
| Board Certification |
0 |
0.18 |
| Patient Safety |
0 |
0.18 |
| Dry Eye |
0 |
0.15 |
| Allergic Contact Dermatitis |
0 |
0.13 |
| Allergens |
0 |
0.09 |
| Allergy |
0 |
0.09 |
| Calcineurin Inhibitor |
0 |
0.09 |
| Contact Dermatitis |
0 |
0.09 |
| Continuing Medical Education |
0 |
0.09 |
| Eczema |
0 |
0.09 |
| Europe |
0 |
0.09 |
| Keratitis |
0 |
0.09 |
| Oregon |
0 |
0.09 |
| Severity Index |
0 |
0.09 |
| Shock |
0 |
0.09 |
| Skin and Soft Tissue Infection |
0 |
0.09 |
| Skin Lesion |
0 |
0.09 |
| Steroids |
0 |
0.09 |